Skip to main content
NCBI home page

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

Research Square logoLink to Research Square
[Preprint]. 2023 Feb 13:rs.3.rs-2570782. [Version 1] doi: 10.21203/rs.3.rs-2570782/v1

NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model

Hampartsoum B Barsoumian 1, Kewen He 2, Ethan Hsu 3, Genevieve Bertolet 4, Duygu Sezen 5, Yun Hu 6, Maria Angelica Cortez 7, James W Welsh 8
PMCID: PMC9949246  PMID: 36824846

Abstract

Radiotherapy (XRT), a well-known activator of the inflammasome and immune priming, is in part capable of reversing resistance to anti-PD1 treatment. Although NLRP3 is typically observed for its role in exacerbating XRT-induced tissue damage, the NLRP3 inflammasome can also be protective and augment the effect of XRT when used in proper dosing and sequencing. However, whether NLRP3 agonist boosts radiation-induced immune priming and promote abscopal responses in anti-PD1 resistant model is still unknown. Therefore, in this study, we paired intratumoral injection of an NLRP3 agonist with XRT to stimulate the immune system in both wild type (344SQ-P) and anti-PD1 resistant (344SQ-R) murine-implanted lung adenocarcinoma models. We found that the combination of XRT + NLPR3 agonist enhanced control of implanted lung adenocarcinoma primary as well as secondary tumors in a radiological dose-dependent manner, in which 12Gy × 3 fractions of stereotactic XRT was better than 5Gy × 3, while 1Gy × 2 did not improve the NLRP3 effect. Survival and tumor growth data also showed significant abscopal response with the triple therapy (12Gyx3 + NLRP3 agonist + α-PD1) in both 344SQ-P and 344SQ-R aggressively growing models. Multiple pro-inflammatory cytokines (IL-1b, IL-4, IL-12, IL-17, IFN-γ and GM-CSF) were elevated in the serum of mice treated with XRT + NLRP3 or triple therapy. The Nanostring results showed that NLRP3 agonist is capable of increasing antigen presentation, innate function, and T-cell priming. This study can be of particular importance to treat patients with immunologically-cold solid tumors whom are also refractory to prior checkpoint treatments.

Keywords: Radiotherapy, Immunotherapy, NLRP3, Immune priming, Abscopal effect

Introduction

Critical to the health of an organism is its ability to maintain internal physiological homeostasis. When threats arise from within or from without that perturb this stable equilibrium, it triggers an immune response to address, contain, and mitigate the threat, and, subsequently, repair the damage sustained. This highly complex process is referred to as inflammatory response [1]. One of the critical mediators of inflammation is a multi-protein complex known as the inflammasome. The inflammasome consists of three components: 1) a NACHT, LRR, and PYD domain - containing protein (NLRP, the best studied of which is NLRP3); 2) a cysteine protease pro-caspase-1; and 3) an apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), which serves as an adaptor, linking the NLRP and caspase-1 together [2]. NLRP3 and the other NLRPs are what are known as pattern recognition receptors (PRRs). This class of molecules recognizes molecular patterns that are associated with common threats to the body. These come in two forms: pathogen-associated molecular patterns (PAMPs), which signify the presence of disease-causing microbes, and damage-associated molecular patterns (DAMPs), which detect the signs of tissue injury [3]. When an NLRP recognizes a particular PAMP or DAMP it triggers the recruitment of the ASCs and pro-caspase-1 in a large signaling complex. Within this complex, pro-caspase-1 undergoes self-cleavage to produce the mature, enzymatically active caspase-1. Caspase-1, in turn, cleaves pro-IL-1 and pro-IL-18 into their active forms, IL-1β and IL-18. These cytokines act in an autocrine or paracrine fashion to initiate the activation of multiple signaling cascades associated with inflammatory response, including NF-κB, PI3K, and MAP kinase pathways [4].

Stereotactic Body Radiation Therapy (SBRT) is an FDA approved technique used in clinical settings to treat solid tumors that enables the delivery of high doses of radiation with reduced damage to surrounding normal tissue. Hypo-fractionated SBRT (5 or less fractions) have been shown to possess immunological benefits by releasing tumor-associated antigens as well as DAMPs, therefore increasing the activation status of antigen presenting cells (APCs) and initiating the immune-priming process [5–8]. The successful priming of T-cells leads to enhanced primary tumor control and promotes abscopal responses at metastatic tumor sites, especially when combined with checkpoint inhibitors, such as anti-PD1 and anti-CTLA-4 [9–11].

In our previous work, we showed that radiotherapy (XRT) is in part capable of reversing resistance to anti-PD1 treatment through the upregulation of MHC-I expression in the tumor microenvironment (TME) and production of type-I interferons [12]. In this current paper, we sought to combine XRT with an NLRP3 agonist to further boost the priming process and generate systemic antitumor responses in murine-implanted lung adenocarcinoma models.

Materials And Methods

Mice and cell lines

10–12 weeks old male 129Sv/Ev mice were used and bred inhouse. All animal procedures were conducted in accordance with the rules and regulations of UT MD Anderson’s IACUC committee. The 344SQ-Parental (344SQ-P) lung adenocarcinoma cell line was a generous gift from Dr. Jonathan Kurie at MD Anderson Cancer Center. The 344SQ anti-PD1 resistant cell line (344SQ-R) was previously developed in the Welsh lab under anti-PD1 pressure and reported accordingly [12].

Tumor inoculation and treatments

to establish primary and secondary tumors, 344SQ-P lung adenocarcinoma cells were subcutaneously injected into the right (4 × 105) and left (1 × 105) hind legs of 129Sv/Ev mice. Alternatively, 344SQ-R was established bilaterally in the right (1 × 105) and left (0.5 × 105) hind legs. Tumors were measured twice per week using digital calipers. Mice were sacrificed when either primary or secondary tumors reached 14mm in diameter. XRT was locally delivered to primary tumors when they reached a size of ~7mm using a Cesium source, while shielding the rest of the body. Lungs were collected at experimental endpoint and stained with Bouin’s fixative solution (Thomas Scientific, Cat# C001X58) to visualize and count the lung metastases.

Drugs and antibodies

NLRP3 agonist was provided by BMS. The drug was injected intratumorally (i.t.) at a dose of 0.3 mg/kg on days 9, 14, and 21 post primary tumor inoculation, dissolved in 100 μl sterile PBS. Anti-PD1 antibody with silenced Fc portion was also provided by BMS. Anti-PD1 was administered intraperitoneally (i.p.) at a dose of 200 μg per injection in 250 μl of sterile PBS.

RT-PCR

Peritoneal macrophages were harvested from naive 129Sv/Ev and panned in culture prior to lysis and RNA extraction. 344SQ-P and 344SQ-R cell lines were also cultured (37°, 5% CO2) for 2–3 passages prior to lysis and RNA extraction. RNA from all samples was converted to cDNA using iScript cDNA Synthesis Kit from Bio-Rad (Cat#1725035). Primers used were: NLRP3 forward 5’ to 3’ ATT ACC CGC CCG AGA AAG G, and NLRP3 Reverse 5’ to 3’ TCG CAG CAA AGA TCC ACA CAG. Samples were run on Bio-Rad CFX96 Real-Time System.

NanoString molecular analysis

Either 344SQ-P or 344SQ-R models were bilaterally established in 129Sv/Ev mice. XRT was delivered to primary tumors on days 6, 7, 8. NLRP3 agonist was injected i.t. on days 9 and 13. On day 14 primary tumors were harvested, RNA extracted using Qiagen kit, and submitted to MDA molecular core to run the NanoString nCounter PanCancer Panel of 770 immune-relevant genes including 15 housekeeping genes. Data was analyzed using nSolver software and advanced analysis was applied to graph the pathway scores.

Statistics

Survival percentages were reported using the Kaplan–Meier method and groups were compared with log-rank tests on GraphPad Prism 9 software. Two-way analysis of variance (ANOVA) was used to compare tumor growth curves. Where indicated, Student’s t tests were used to assess significance between individual groups. Statistical significance was defined at P≤0.05.

Results

1. NLRP3 agonist improves radiation-induced primary tumor control.

We first explored the efficacy of combining the NLRP3 agonist with different doses of XRT on tumor growth in vivo. We established two bilateral tumor models, 344SQ-P and 344SQ-R, and delivered unilateral XRT to primary tumors, intratumor NLRP3 agonist, and intraperitoneal α-PD1 injections, as shown in Figure 1a. 1 Gy XRT, either with or without NLRP3/α-PD1, was unable to extend survival (all P>0.05 vs. XRT, supplementary figure S1a). Both 12 Gy and 5 Gy XRT + NLRP3 ± α-PD1 prolonged survival in both the 344SQ-P (all P<0.01 vs. XRT, Figure 1b, supplementary figure S1b) and 344SQ-R groups (all P<0.01 vs. XRT, Figure 1c, supplementary figure S1c). Consistent with the survival data, no enhanced tumor control was achieved for 1 Gy XRT, either with or without NLRP3/α-PD1 (all P>0.05 vs. XRT, supplementary figure S1d). Addition of the NLRP3 agonist significantly improved tumor control of 12 Gy and 5 Gy XRT in both 344SQ-P (P<0.0001 vs. XRT, Figure 1d; P=0.0015 vs. XRT, supplementary figure S1e) and 344SQ-R models (all P<0.0001 vs. XRT, Figure 1e, supplementary figure S1f). Moreover, the 12 Gy + NLRP3 agonist achieved better primary tumor control than the 5 Gy treatment regimen in 344SQ-P model. The addition of α-PD1 did significantly improve performance of the NLRP3 agonist in combination with 5 Gy XRT in both tumor models (P=0.017 and P<0.0001, respectively, supplementary figure S1e and S1f); however, α-PD1 did not boost the strength of 12 Gy XRT + NLRP3 combination in regards to primary tumors (all P>0.05, Figure 1d and 1e). Therefore, the combination of XRT + NLPR3 agonist halted the growth rate of primary tumors in a radiological dose-dependent manner.

Figure 1. NLRP3 agonist improves radiation-induced primary tumor control.

Figure 1

Open in a new tab

(a) Establishment of 344SQ-P and 344SQ-R models and treatment strategy. On day 0, 5×105 cells were subcutaneously injected into the right leg to form the “primary tumor” (n=5 mice/group). Three days later, 1×105 cells were subcutaneously injected in the left leg to form the “secondary” tumor. Anti-PD1 was intraperitoneally (i.p.) started on day 5. XRT to the primary tumors started on day 6. NLRP3 agonist was intratumorally injected (i.t.) to the primary tumor starting on day 9 for 3 doses. Survival curves of 12 Gy in 344SQ-P (b) and 344SQ-R models (c). Tumor growth curves of primary tumors of 12 Gy in 344SQ-P (d) and 344SQ-R models (e). Survival was plotted by the Kaplan-Meier method. Two-way analysis of variance with multiple comparisons was used to analyze the tumor growth curves. **P <0.01; ****P <0.0001; ns, not significant.

2. NLRP3 agonist increases inflammasome-related immune priming.

The NLRP3 inflammasome is a key component of the pro-inflammatory response of macrophages [13]. NLRP3 is also expressed in tumor cells and is related to immune resistance through PD-L1/NLRP3 inflammasome signaling [14]. It has been well documented that radiation can trigger NLRP3 inflammasome activation via multiple mechanisms [15]. Hence, we assessed the effect of XRT on NLRP3 expression at the mRNA level in macrophages and tumor cells separately in vitro. XRT enhanced NLRP3 expression in peritoneal macrophages in a dose-dependent manner (Figure 2a). In the tumor cells, Nlrp3 was upregulated 24h after XRT, with expression peaking following a dose of 6 Gy at this time point. This increase was not significant in 344SQ-P cells (Figure 2b), but it was in 344SQ-R cells (P<0.05, Figure 2c).

Figure 2. NLRP3 agonist increases inflammasome-related immune priming.

Figure 2

Open in a new tab

Nlrp3 expression after XRT (a-c). The expression of NLRP3 in peritoneal macrophages tested 24h after treated with different doses of RT (0 Gy, 2 Gy, 6 Gy and 12 Gy) by qRT-PCR (a). The expression of NLRP3 in 344SQ-P (b) and 344S-R (c) cells 3 h and 24 h after treated with different doses of RT (0 Gy, 2 Gy, 6 Gy, and 12 Gy). Data are presented as mean values ± SD. *P<0.05, ** P <0.01, unpaired t test. The results of NanoString analysis of 770 immune-related genes (d-g). The expression of Nlrp3, Il1b, and Il18 in 344SQ-P (d) and 344SQ-R (e) models. The scores of immune pathways including innate immunity, antigen processing, macrophage function, interleukins, adaptive immunity, and T cell function in 344SQ-P (f) and 344SQ-R (g) tumors. *P<0.05, **P <0.01.

To explore the mechanism by which the combination of XRT and the NLRP3 agonist improved primary tumor control, we isolated RNA from the primary tumors of both lines and analyzed the differential regulation of 770 immune related genes using the nCounter PanCancer Immune Profiling Panel from NanoString. Since the XRT regimen of 12 Gy × 3 fractions elicited the best response, we used this dose moving forward. The NLRP3 agonist significantly increased the expression of Nlrp3 and the inflammasome cytokines Il1b and Il18 relative to untreated controls or mice treated with XRT in 344SQ-P tumors (P<0.05, Figure 2d). The addition of α-PD1 to XRT + NLRP3 further increased the expression of Il1b (P=0.010) and Il18 (P=0.014) relative to XRT + NLRP3 group. Unlike in the 344SQ-P tumors, XRT alone was able to significantly elevate the expression of these genes, and neither addition of the NLRP3 agonist alone nor the agonist in concert with α-PD1 was able to further significantly increase this (Figure 2e). Baseline expression of Nlrp3 and Il18 was significantly higher in 344SQ-R compared to 344SQ-P (both P<0.05, supplementary table S1), so the lack of upregulation in 344SQ-P cells treated with XRT alone was not due to Nlrp3 levels already being elevated. Thus, 344SQ-R cells had higher initial expression of Nlrp3, and this expression, as well as the expression of the inflammasome-related cytokines Il1b and Il18, were further increased following agonism of NLRP3.

Most measured immune pathways were upregulated in the XRT + NLRP3 ± α-PD1 groups, as compared to control or XRT alone, and this was true for both tumor lines (supplementary figure 2a and 2b). In particular, the pathways related to innate immunity, antigen processing, macrophage function, interleukins, adaptive immunity, and T cell function were drastically enhanced in the treatments containing XRT + NLRP3 in both 344SQ-P (Figure 2f) and 344SQ-R (Figure 2g) models. Predictably, the addition of α-PD1 to XRT + NLRP3 reflected enhanced effect on gene expression in the 344SQ-P model vs. 344SQ-R.

3. NLRP3 agonist promotes abscopal responses.

The benefit of the NLRP3 agonist was not only limited to the primary tumors, but also impacted the growth of secondary, unirradiated tumors. As with the primary tumors, both 12 Gy and 5 Gy XRT in combination with NLRP3 agonist significantly depressed the growth of secondary tumors in the 344SQ-P model (Figure 3a, supplementary figure S3a) and 344SQ-R (Figure 3b, supplementary figure S3b) models (all P<0.05 vs. XRT). Surprisingly, this abscopal response was dramatically enhanced by the addition of α-PD1 to XRT + NLRP3 in the 344SQ-R (P=0.001, vs. XRT + NLRP3, Figure 3b), but the same was not seen in the 344SQ-P (P=0.321, vs. XRT + NLRP3, Figure 3a). These treatments also strongly reduced lung metastases in 344SQ-P and 344SQ-R models. Both 12 Gy and 5 Gy XRT regimens in concert with the NLRP3 agonist and α-PD1 strongly reduced lung metastases in 344SQ-P and 344SQ-R models (Figure 3c and 3d, supplementary figure S3c).

Figure 3. NLRP3 agonist promotes abscopal responses.

Figure 3

Open in a new tab

(a and b) Tumor growth curves of secondary tumors of 12Gy in 344SQ-P (a) and in 344SQ-R (b). The lung metastases count (normalized by the day of scarified) of mice received different treatments in 344SQ-P (c) and 344 SQ-R (d). Multiple serum pro-inflammatory cytokines in different treatment groups from 344SQ-P (e) and 344SQ-R (f) models. Two-way analysis of variance with multiple comparisons was used to analyze the tumor growth curves and unpaired ttest was used in comparison of lung metastases and cytokines. Data are presented as mean values ± SD. *P<0.05, **P <0.01; ****P <0.0001; ns, not significant.

In addition to secondary tumor shrinkage and reduced lung metastases, multiple pro-inflammatory cytokines were elevated in the serum of mice treated with XRT+NLRP3 or triple therapy, as assessed by multiplex ELISA. IL-1b, IL-4, IL-12, IL-17, IFN-γ and GM-CSF were significantly increased in the combination of 12Gy XRT and NLRP3 agonist compared to XRT alone in 344SQ-P model (all P<0.05, Figure 3e). Although none of these cytokines were significantly increased in XRT + NLRP3 as to XRT alone in 344SQ-R model, IFN-γ and GM-CSF were drastically increased by the addition of α-PD1 to XRT + NLRP3 (all P<0.05, Figure 3f).

Discussion

Immune priming is the first fundamental step in initiating an immune reaction. T-cell priming requires the engagement of a T-cell receptor (TCR) with MHC-I or MHC-II molecules on APCs loaded with tumor associated antigens. This signal 1 of priming in addition to proper costimulation (signal 2) lead to inflammatory cytokines production by APCs (signal 3) and subsequent proliferation/expansion of antigen-specific T-cells. The Nanostring results in this study show that NLRP3 agonist is capable of increasing antigen presentation, innate function, and T-cell priming. XRT in its turn further helps the NLRP3 agonist by releasing antigens and DAMPs. The primed T-cells traffic systemically and exert effector functions on distant tumors. The only limitation is that most of these T-cells get exhausted quite rapidly, therefore adding checkpoint inhibitors such as anti-PD1 can augment in prolonging the effector functions. Our survival and tumor growth data indeed show significant abscopal response with the triple therapy (12Gyx3 + NLRP3 agonist + α-PD1) in both 344SQ-P and 344SQ-R aggressively growing models.

Although the inflammatory response is a component of the immune system and part of the body’s mechanism for restoring balance, it can be readily co-opted by cancer. The same cytokines that promote immune cell proliferation, migration, and survival can be utilized by various malignancies for those same purposes [16]. The link between inflammation and cancer progression was noted as early as 1983 [17], and since that time it has come to be appreciated that chronic inflammation acts at every single stage of tumor development, including initiation, growth, invasion, and metastasis [18]. The inflammasome is by no means exempt from the inflammatory machinery of which cancer can and will take advantage. NLRP3 is upregulated in a number of cancers, including head-and-neck, gastric, lung, kidney, melanoma, and myelodysplasia, and it often drives cancer progression and immunosuppression, correlating with poor patient outcomes [19, 20].

It should not be assumed from the above, however, that the NLRP3 inflammasome acts unvaryingly in the service of the cancer. On the contrary, a substantial body of evidence attests to the critical role that NLRP3 plays in restraining tumor growth and spread. Mice deficient in NLRP3 have been repeatedly found to be more susceptible to colorectal malignancies [21–24]. NLRP3 was found to be dramatically diminished in the lymphocytes of chronic lymphocytic leukemia (CLL) patients [25]. A pan-cancer analysis of twenty-four different tumor cell lines representing several different tissue types found that, in the majority of cell lines examined, NLRP3 and its associated components were in fact downregulated as compared to normal tissues [20]. In human hepatocellular carcinoma (HCC), components of the NLRP3 inflammasome were found to be either absent or else significantly downregulated. This deficiency corresponded with HCC occurrence, advanced tumor stage, and poor differentiation [26]. However, reactivation of the NLRP3 inflammasome through either direct exogenous transfection of inflammasome components or through stimulation by 17β-estradiol decreased the viability and migratory capacity of HCC cells [27]. Likewise, exogenous overexpression of NLRP3 via plasmid in Ramos B lymphoma and HEK293 cell lines caused significantly slower proliferation and accelerated apoptosis, and halted propagation in vitro [25].

NLRP3 is, therefore a two-edged sword - one that can be wielded by either the immune system or by the cancer. Given the profound influence that inflammation has on both, a treatment modality that could effectively and reliably harness the inflammasome to the benefit of the immune system could prove a potent therapy for improving patient outcomes. For this reason, we paired intratumoral injection of an NLRP3 agonist with XRT in order to stimulate the immune system. Our lab and others have previously shown that irradiation of a tumor can galvanize the immune system, leading to reduced growth and even total clearance of unirradiated metastases [28–31] - a phenomenon known as the abscopal effect [32]. Radiation is a well-known activator of the inflammasome [33]. Although NLRP3 is typically observed and described in its role of exacerbating XRT-induced tissue damage [15, 34–37], the NLRP3 inflammasome can also be protective [38] and, in some cases, actually augment the effect of XRT [39]. Harnessing the positive aspects of NLRP3 agonism, we hereby demonstrated the boosted priming effect and improved systemic antitumor responses with the combined treatment of XRT and NLRP3 agonist, in both wild type and anti-PD1 resistant murine-implanted lung adenocarcinoma models. Therefore, a triple therapy of XRT + NLRP3 agonist + α-PD1 might be an alternative therapeutic approach for patients with immune-resistant lung cancer.

The mechanism whereby NLRP3 hampers tumorigenesis appears to be in promoting the immune response thereto, especially when combined in optimal timing/sequencing with XRT, to generate acute inflammation rather than unwanted chronic inflammation. In our current study, multiple pro-inflammatory cytokines (IL-1b, IL-4, IL-12, IL-17, IFN-γ and GM-CSF) were elevated in the serum of mice treated with XRT + NLRP3 or triple therapy. NanoString analysis of the primary tumor demonstrated that treatments containing XRT + NLRP3 agonist activated multiple immune pathways and genes directly involved in antigen presentation and elevated innate functions. Others have also reported the NLRP3 inflammasome to be essential for the priming and differentiation of IFNγ-producing CD8+ T cells by antigen-presenting dendritic cells (DCs) [40]. In addition, NLRP3 was found to suppress hepatic metastasis of colorectal carcinoma by increasing the production of IL-18, thereby promoting NK cell maturation and cytotoxicity [22]. A Diagram of XRT + NLRP3 immune priming in antigen presenting cells is illustrated in Figure 4. In brief, radiation releases DAMPs that activate Toll-like receptors (TLRs), leading to the activation of NF-kB and production of pro-IL-1, pro-IL-18, and inactive NLRP3 building blocks [41]. The Reactive oxygen species (ROS) produced by radiation also helps the formation of the inflammasome and the agonist used further activates NLRP3 to produce caspase-1. The latter catalysis the formation of mature IL-1 and IL-18 cytokines to trigger a local and systemic immune reaction.

Figure 4. Illustrative diagram of radiation + NLRP3 immune priming in antigen presenting cells.

Figure 4

Open in a new tab

In brief, radiation releases DAMPs that activate Toll-like receptors (TLRs), leading to the activation of NF-kB and production of pro-IL-1, pro-IL-18, and inactive NLRP3 building blocks. The Reactive oxygen species (ROS) produced by radiation also helps the formation of the inflammasome and the agonist used further activates NLRP3 to produce caspase-1. The latter catalysis the formation of mature IL-1 and IL-18 cytokines to trigger a local and systemic immune reaction.

In summary, the combination of XRT + NLPR3 agonist enhanced control of implanted lung adenocarcinoma primary as well as secondary tumors in a radiological dose-dependent manner, in which 12Gy × 3 fractions of stereotactic XRT was better than 5Gy × 3, while 1Gy × 2 did not improve the NLRP3 effect. This study can be of particular importance to treat patients with immunologically-cold solid tumors whom are also refractory to prior checkpoint treatments.

Acknowledgements

The authors would like to thank Bristol Myers Squibb (BMS) for providing the NLRP3 agonist and anti-PD1 antibody.

Funding

This work was supported by Bristol Myers Squibb (BMS) and Cancer Center Support (Core) Grant P30 CA016672 from the National Cancer Institute, NIH, to the University of Texas MD Anderson Cancer Center.

Competing Interests

JWW reports research support from GlaxoSmithKline, Bristol Meyers Squibb, Merck, Nanobiotix, RefleXion, Alkermes, Artidis, Mavu Pharma, Takeda, Varian, Checkmate Pharmaceuticals, HotSpot Therapeutics, Inc., Gilead and Kiromic. JWW serves/served on the scientific advisory board for Legion Healthcare Partners, RefleXion Medical, MolecularMatch, Merck, AstraZeneca, Aileron Therapeutics, OncoResponse, Checkmate Pharmaceuticals, Mavu Pharma, Alpine Immune Sciences, Ventana Medical Systems, Nanobiotix, China Medical Tribune, GI Innovation, Genentech and Nanorobotix. JWW serves as consultant for Lifescience Dynamics Limited. JWW has/had Speaking Engagements for Ventana Medical Systems, US Oncology, Alkermes, Boehringer Ingelheim, Accuray and RSS. JWW holds/held stock or ownership in Alpine Immune Sciences, Checkmate Pharmaceuticals, Healios, Mavu Pharma, Legion Healthcare Partners, MolecularMatch, Nanorobotix, OncoResponse, and RefleXion. JWW has accepted honoraria in the form of travel costs from Nanobiotix, RefleXion, Varian, Shandong University, The Korea Society of Radiology, Aileron Therapeutics and Ventana. JWW has the following patents; MP470 (amuvatinib), MRX34 regulation of PDL1, XRT technique to overcome immune resistance. MD Anderson Cancer Center has a trademark for RadScopal™. The rest of the authors disclosed no competing interests.

Footnotes

Ethics approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee at UT MD Anderson Cancer Center.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

Contributor Information

Hampartsoum B. Barsoumian, The University of Texas MD Anderson Cancer Center

Kewen He, Shandong First Medical University, Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute.

Ethan Hsu, The University of Texas MD Anderson Cancer Center.

Genevieve Bertolet, The University of Texas MD Anderson Cancer Center.

Duygu Sezen, The University of Texas MD Anderson Cancer Center.

Yun Hu, The University of Texas MD Anderson Cancer Center.

Maria Angelica Cortez, The University of Texas MD Anderson Cancer Center.

James W. Welsh, The University of Texas MD Anderson Cancer Center

Data Availability

The datasets generated during the current study are available from the corresponding author on reasonable request.

References

  • 1.Chen L., Deng H., Cui H., Fang J., Zuo Z., Deng J., Li Y., Wang X., Zhao L., Inflammatory responses and inflammation-associated diseases in organs, Oncotarget, 9 (2018) 7204–7218. 10.18632/oncotarget.23208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Sharma M., de Alba E., Structure, Activation and Regulation of NLRP3 and AIM2 Inflammasomes, Int J Mol Sci, 22 (2021). 10.3390/ijms22020872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Roh J.S., Sohn D.H., Damage-Associated Molecular Patterns in Inflammatory Diseases, Immune Netw, 18 (2018) e27. 10.4110/in.2018.18.e27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Li D., Ren W., Jiang Z., Zhu L., Regulation of the NLRP3 inflammasome and macrophage pyroptosis by the p38 MAPK signaling pathway in a mouse model of acute lung injury, Mol Med Rep, 18 (2018) 4399–4409. 10.3892/mmr.2018.9427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ashrafizadeh M., Farhood B., Eleojo Musa A., Taeb S., Najafi M., Damage-associated molecular patterns in tumor radiotherapy, Int Immunopharmacol, 86 (2020) 106761. 10.1016/j.intimp.2020.106761. [DOI] [PubMed] [Google Scholar]
  • 6.Kratky W., Reis e Sousa C., Oxenius A., Sporri R., Direct activation of antigen-presenting cells is required for CD8+ T-cell priming and tumor vaccination, Proc Natl Acad Sci U S A, 108 (2011) 17414–17419. 10.1073/pnas.1108945108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Deng L., Liang H., Xu M., Yang X., Burnette B., Arina A., Li X.D., Mauceri H., Beckett M., Darga T., Huang X., Gajewski T.F., Chen Z.J., Fu Y.X., Weichselbaum R.R., STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors, Immunity, 41 (2014) 843–852. 10.1016/j.immuni.2014.10.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Burnette B.C., Liang H., Lee Y., Chlewicki L., Khodarev N.N., Weichselbaum R.R., Fu Y.X., Auh S.L., The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity, Cancer Res, 71 (2011) 2488–2496. 10.1158/0008-5472.CAN-10-2820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Liu Y., Dong Y., Kong L., Shi F., Zhu H., Yu J., Abscopal effect of radiotherapy combined with immune checkpoint inhibitors, J Hematol Oncol, 11 (2018) 104. 10.1186/s13045-018-0647-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Dewan M.Z., Galloway A.E., Kawashima N., Dewyngaert J.K., Babb J.S., Formenti S.C., Demaria S., Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody, Clin Cancer Res, 15 (2009) 5379–5388. 10.1158/1078-0432.CCR-09-0265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Hu Y., Paris S., Barsoumian H., Abana C.O., He K., Wasley M., Younes A.I., Masrorpour F., Chen D., Yang L., Dunn J.D., Zhang J., Gandhi S., Nguyen Q.N., Cortez M.A., Welsh J., Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects, Int J Radiat Oncol Biol Phys, 111 (2021) 647–657. 10.1016/j.ijrobp.2021.06.041. [DOI] [PubMed] [Google Scholar]
  • 12.Wang X., Schoenhals J.E., Li A., Valdecanas D.R., Ye H., Zang F., Tang C., Tang M., Liu C.G., Liu X., Krishnan S., Allison J.P., Sharma P., Hwu P., Komaki R., Overwijk W.W., Gomez D.R., Chang J.Y., Hahn S.M., Cortez M.A., Welsh J.W., Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy, Cancer Res, 77 (2017) 839–850. 10.1158/0008-5472.CAN-15-3142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Escolano J.C., Taubenberger A.V., Abuhattum S., Schweitzer C., Farrukh A., Del Campo A., Bryant C.E., Guck J., Compliant Substrates Enhance Macrophage Cytokine Release and NLRP3 Inflammasome Formation During Their Pro-Inflammatory Response, Front Cell Dev Biol, 9 (2021) 639815. 10.3389/fcell.2021.639815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Theivanthiran B., Evans K.S., DeVito N.C., Plebanek M., Sturdivant M., Wachsmuth L.P., Salama A.K., Kang Y., Hsu D., Balko J.M., Johnson D.B., Starr M., Nixon A.B., Holtzhausen A., Hanks B.A., A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy, J Clin Invest, 130 (2020) 2570–2586. 10.1172/JCI133055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Huang S., Che J., Chu Q., Zhang P., The Role of NLRP3 Inflammasome in Radiation-Induced Cardiovascular Injury, Front Cell Dev Biol, 8 (2020) 140. 10.3389/fcell.2020.00140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Hanahan D., Weinberg R.A., Hallmarks of cancer: the next generation, Cell, 144 (2011) 646–674. 10.1016/j.cell.2011.02.013. [DOI] [PubMed] [Google Scholar]
  • 17.Balkwill F., Mantovani A., Inflammation and cancer: back to Virchow?, Lancet, 357 (2001) 539–545. 10.1016/s0140-6736(00)04046-0. [DOI] [PubMed] [Google Scholar]
  • 18.Solinas G., Marchesi F., Garlanda C., Mantovani A., Allavena P., Inflammation-mediated promotion of invasion and metastasis, Cancer Metastasis Rev, 29 (2010) 243–248. 10.1007/s10555-010-9227-2. [DOI] [PubMed] [Google Scholar]
  • 19.Hamarsheh S., Zeiser R., NLRP3 Inflammasome Activation in Cancer: A Double-Edged Sword, Front Immunol, 11 (2020) 1444. 10.3389/fimmu.2020.01444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Ju M., Bi J., Wei Q., Jiang L., Guan Q., Zhang M., Song X., Chen T., Fan J., Li X., Wei M., Zhao L., Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer, Brief Bioinform, (2020). 10.1093/bib/bbaa345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Allen I.C., TeKippe E.M., Woodford R.M., Uronis J.M., Holl E.K., Rogers A.B., Herfarth H.H., Jobin C., Ting J.P., The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer, J Exp Med, 207 (2010) 1045–1056. 10.1084/jem.20100050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Dupaul-Chicoine J., Arabzadeh A., Dagenais M., Douglas T., Champagne C., Morizot A., Rodrigue-Gervais I.G., Breton V., Colpitts S.L., Beauchemin N., Saleh M., The Nlrp3 Inflammasome Suppresses Colorectal Cancer Metastatic Growth in the Liver by Promoting Natural Killer Cell Tumoricidal Activity, Immunity, 43 (2015) 751–763. 10.1016/j.immuni.2015.08.013. [DOI] [PubMed] [Google Scholar]
  • 23.Zaki M.H., Boyd K.L., Vogel P., Kastan M.B., Lamkanfi M., Kanneganti T.D., The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis, Immunity, 32 (2010) 379–391. 10.1016/j.immuni.2010.03.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Zaki M.H., Vogel P., Body-Malapel M., Lamkanfi M., Kanneganti T.D., IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation, J Immunol, 185 (2010) 4912–4920. 10.4049/jimmunol.1002046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Salaro E., Rambaldi A., Falzoni S., Amoroso F.S., Franceschini A., Sarti A.C., Bonora M., Cavazzini F., Rigolin G.M., Ciccone M., Audrito V., Deaglio S., Pelegrin P., Pinton P., Cuneo A., Di Virgilio F., Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death, Sci Rep, 6 (2016) 26280. 10.1038/srep26280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Wei Q., Mu K., Li T., Zhang Y., Yang Z., Jia X., Zhao W., Huai W., Guo P., Han L., Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression, Lab Invest, 94 (2014) 52–62. 10.1038/labinvest.2013.126. [DOI] [PubMed] [Google Scholar]
  • 27.Wei Q., Guo P., Mu K., Zhang Y., Zhao W., Huai W., Qiu Y., Li T., Ma X., Liu Y., Chen X., Han L., Estrogen suppresses hepatocellular carcinoma cells through ERβ-mediated upregulation of the NLRP3 inflammasome, Lab Invest, 95 (2015) 804–816. 10.1038/labinvest.2015.63. [DOI] [PubMed] [Google Scholar]
  • 28.Caetano M.S., Younes A.I., Barsoumian H.B., Quigley M., Menon H., Gao C., Spires T., Reilly T.P., Cadena A.P., Cushman T.R., Schoenhals J.E., Li A., Nguyen Q.N., Cortez M.A., Welsh J.W., Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses, Clin Cancer Res, 25 (2019) 7576–7584. 10.1158/1078-0432.Ccr-19-0795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Chen D., Barsoumian H.B., Yang L., Younes A.I., Verma V., Hu Y., Menon H., Wasley M., Masropour F., Mosaffa S., Ozgen T., Klein K., Cortez M.A., Welsh J.W., SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer, Cancer Immunol Res, 8 (2020) 883–894. 10.1158/2326-6066.Cir-19-0744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Theelen W., Chen D., Verma V., Hobbs B.P., Peulen H.M.U., Aerts J., Bahce I., Niemeijer A.L.N., Chang J.Y., de Groot P.M., Nguyen Q.N., Comeaux N.I., Simon G.R., Skoulidis F., Lin S.H., He K., Patel R., Heymach J., Baas P., Welsh J.W., Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials, Lancet Respir Med, 9 (2021) 467–475. 10.1016/s2213-2600(20)30391-x. [DOI] [PubMed] [Google Scholar]
  • 31.Welsh J.W., Tang C., de Groot P., Naing A., Hess K.R., Heymach J.V., Papadimitrakopoulou V.A., Cushman T.R., Subbiah V., Chang J.Y., Simon G.R., Ramapriyan R., Barsoumian H.B., Menon H., Cortez M.A., Massarelli E., Nguyen Q., Sharma P., Allison J.P., Diab A., Verma V., Raju U., Shaaban S.G., Dadu R., Cabanillas M.E., Wang K., Anderson C., Gomez D.R., Hahn S., Komaki R., Hong D.S., Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses, Cancer Immunol Res, 7 (2019) 1903–1909. 10.1158/2326-6066.Cir-18-0793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Demaria S., Ng B., Devitt M.L., Babb J.S., Kawashima N., Liebes L., Formenti S.C., Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated, Int J Radiat Oncol Biol Phys, 58 (2004) 862–870. 10.1016/j.ijrobp.2003.09.012. [DOI] [PubMed] [Google Scholar]
  • 33.Stoecklein V.M., Osuka A., Ishikawa S., Lederer M.R., Wanke-Jellinek L., Lederer J.A., Radiation exposure induces inflammasome pathway activation in immune cells, J Immunol, 194 (2015) 1178–1189. 10.4049/jimmunol.1303051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Ito H., Kimura H., Karasawa T., Hisata S., Sadatomo A., Inoue Y., Yamada N., Aizawa E., Hishida E., Kamata R., Komada T., Watanabe S., Kasahara T., Suzuki T., Horie H., Kitayama J., Sata N., Yamaji-Kegan K., Takahashi M., NLRP3 Inflammasome Activation in Lung Vascular Endothelial Cells Contributes to Intestinal Ischemia/Reperfusion-Induced Acute Lung Injury, J Immunol, 205 (2020) 1393–1405. 10.4049/jimmunol.2000217. [DOI] [PubMed] [Google Scholar]
  • 35.Li X., Gong Y., Li D., Xiang L., Ou Y., Jiang L., Shu P., Liu X., Guo F., Qin D., Mo Z., Qin Q., Wang X., Wang Y., Low-Dose Radiation Therapy Promotes Radiation Pneumonitis by Activating NLRP3 Inflammasome, Int J Radiat Oncol Biol Phys, 107 (2020) 804–814. 10.1016/j.ijrobp.2020.02.643. [DOI] [PubMed] [Google Scholar]
  • 36.Liu Y.G., Chen J.K., Zhang Z.T., Ma X.J., Chen Y.C., Du X.M., Liu H., Zong Y., Lu G.C., NLRP3 inflammasome activation mediates radiation-induced pyroptosis in bone marrow-derived macrophages, Cell Death Dis, 8 (2017) e2579. 10.1038/cddis.2016.460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Sohn S.H., Lee J.M., Park S., Yoo H., Kang J.W., Shin D., Jung K.H., Lee Y.S., Cho J., Bae H., The inflammasome accelerates radiation-induced lung inflammation and fibrosis in mice, Environ Toxicol Pharmacol, 39 (2015) 917–926. 10.1016/j.etap.2015.02.019. [DOI] [PubMed] [Google Scholar]
  • 38.Wu T., Gao J., Liu W., Cui J., Yang M., Guo W., Wang F.Y., NLRP3 protects mice from radiation-induced colon and skin damage via attenuating cGAS-STING signaling, Toxicol Appl Pharmacol, 418 (2021) 115495. 10.1016/j.taap.2021.115495. [DOI] [PubMed] [Google Scholar]
  • 39.Han C., Godfrey V., Liu Z., Han Y., Liu L., Peng H., Weichselbaum R.R., Zaki H., Fu Y.X., The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation, Sci Immunol, 6 (2021). 10.1126/sciimmunol.abc6998. [DOI] [PubMed] [Google Scholar]
  • 40.Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y., Ortiz C., Vermaelen K., Panaretakis T., Mignot G., Ullrich E., Perfettini J.L., Schlemmer F., Tasdemir E., Uhl M., Génin P., Civas A., Ryffel B., Kanellopoulos J., Tschopp J., André F., Lidereau R., McLaughlin N.M., Haynes N.M., Smyth M.J., Kroemer G., Zitvogel L., Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors, Nat Med, 15 (2009) 1170–1178. 10.1038/nm.2028. [DOI] [PubMed] [Google Scholar]
  • 41.Shao B.Z., Xu Z.Q., Han B.Z., Su D.F., Liu C., NLRP3 inflammasome and its inhibitors: a review, Front Pharmacol, 6 (2015) 262. 10.3389/fphar.2015.00262. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets generated during the current study are available from the corresponding author on reasonable request.

Articles from Research Square are provided here courtesy of American Journal Experts

RESOURCES